James Dean

James Dean

Auto-generated profile, based on publicly available information

James Dean

Medicines Evaluation Unit, Manchester, United Kingdom

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JDJames Dean
James Dean
UKUmme Kolsum
Umme Kolsum
PHPaul Hitchen
Paul Hitchen
VGVanadana Gupta
Vanadana Gupta
DSDave Singh
Dave Singh
We have used impulse oscillometry to identify COPD patients with tidal expiratory flow limitation (EFL), which is a measurement related to small airway disease. We report that 37.4% of COPD patients had EFL; these patients had multiple clinical characteristics of more severe disease including lower forced expiratory volume in 1 second values, greater hyperinflation, reduced exercise performance, and increased small airway impairment. We highlight that EFL can be used to identify a subgroup of COPD patients with distinct characteristics associated with small airway disease.

23 November 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
AHAndrew Higham
Andrew Higham
ABAugusta Beech
Augusta Beech
JDJames Dean
James Dean
DSDave Singh
Dave Singh
There is increasing interest in type 2 (T2) inflammation in COPD [1]. COPD patients with higher blood eosinophil counts (BECs) have a greater T2 profile, including interleukin (IL)-13 expression, in bronchial brush and sputum samples [2–4]. IL-13 upregulates inducible nitric oxide synthase, increasing fractional exhaled nitric oxide (FENO) levels.

9 December 2020 in Respiratory Research
Verified
Journal Article
Open access
PDF file
JDJames Dean
James Dean
CPCatalina Panainte
Catalina Panainte
NKNaimat Khan
Naimat Khan
DSDave Singh
Dave Singh
Background: The effects of triple therapy on gas trapping in COPD are not fully understood. We evaluated the effects of the long acting bronchodilator components of the extrafine single inhaler triple therapy beclometasone dipropionate/formoterol/glycopyrronium (BDP/F/G) pMDI on gas trapping. Methods: This open-label, randomised, single centre, 2-way cross-over study recruited 23 COPD patients taking inhaled corticosteroid combination treatments and with residual volume (RV) > 120% predicted at screening. Inhaled BDP was taken during run-in and washout periods. Baseline lung function (spirometry, lung volumes, oscillometry) was measured over 12 h prior to randomisation to BDP/F/G or BDP/F for 5 days followed by washout and crossover. Lung function was measured prior to dosing on day 1 and for 12 h post-dose on day 5. Results: Co-primary endpoint analysis: BDP/F/G had a greater effect than BDP/F on FEV1 area under the curve over 12 h (AUC0–12) (mean difference 104 mls, p = 0.0071) and RV AUC0–12 (mean difference − 163 mls, p = 0.0028). Oscillometry measurements showed a greater effect of BDP/F/G on the difference between resistance at 5 and 20 Hz (R5–R20) AUC0–12, which measures small airway resistance (mean difference − 0.045 kPa/L/s, p = 0.0002). Comparison of BDP/F with the baseline measurements (BDP alone) showed that F increased FEV1 AUC0–12 (mean difference 227 mls) and improved RV AUC0–12 (mean difference − 558 mls) and R5–R20 AUC0–12 (mean difference − 0.117 kPa/L/s), all p < 0.0001. Conclusions: In COPD patients with hyperinflation, the G and F components of extrafine BDP/F/G improved FEV1, RV and small airway function. These long acting bronchodilators target small airway function, thereby improving gas trapping and airflow. Trial registration The study was retrospectively registered at ClinicalTrials.gov on 15th February 2019 (No.: NCT03842904, https://clinicaltrials.gov/ct2/show/NCT03842904).

2 March 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
ABAugusta Beech
Augusta Beech
NJNatalie Jackson
Natalie Jackson
JDJames Dean
James Dean
DSDave Singh
Dave Singh
The question addressed by the study: Small airway collapse during expiration, known as expiratory flow limitation (EFL), can be detected using oscillometry and is associated with worse clinical outcomes in COPD. This study investigated the prevalence of EFL in a cohort of highly symptomatic patients, evaluated clinical and lung function characteristics of patients with EFL and studied the repeatability of EFL over 6 months.Materials/patients and methods: 70 patients were recruited. Clinical characteristics and lung function metrics were collected at baseline and 6 months. Impulse oscillometry was used to detect the presence of EFL. Patients were defined as EFLHigh(change in reactance measured at 5 Hz (ΔX5) ≥0.28 kPa·L−1·s−1); EFLIntermediate(ΔX50.1–0.27 kPa·L−1·s−1) and EFLNone(ΔX5<0.1 kPa·L−1·s−1).Results: EFLHighwas present in 47.8% of patients at baseline. ΔX5showed excellent repeatability over 6 months (ρ=0.78, p<0.0001, intraclass correlation coefficient (ICC) 0.88), with the best repeatability observed in EFLNoneand EFLHighpatients (ICC 0.77 and 0.65, respectively). Compared to EFLNonepatients, EFLHighhad a higher body mass index, worse health-related quality of life and increased peripheral airway resistance. EFLIntermediatewas more variable over time with less severe physiological impairment.Answer to the question: Overall, these data indicate that EFLHighis a common, and relatively stable, component of disease pathophysiology in highly symptomatic COPD patients. EFLHighwas also associated with worse quality of life and obesity.

26 August 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
JDJames Dean
James Dean
NJNatalie Jackson
Natalie Jackson
BKBrett Keidel-Morgan
Brett Keidel-Morgan
DHDaniel Hamer
Daniel Hamer
DSDave Singh
Dave Singh
Tidal-breathing methacholine challenges are now recommended by guidelines, to avoid the bronchoprotective effects of deep inhalation. This study compared different tidal breathing methacholine challenge methods; assessed the agreement between tidal dosimetric and continuous output challenges; and assessed challenge repeatability with different methods.15 asthma patients performed dosimetric challenges and a continuous-output breath-actuated challenge, all ≥3 days apart. All subjects had a pre-bronchodilator forced expiratory volume in 1 s (FEV1) ≥65% predicted, and a cumulative dose causing a 20% reduction in FEV1(PD20) <1.2 mg.Of the dosimetric challenges, one method increased methacholine concentration (standard dosimetric challenge), and one adjusted nebuliser output time to increase dose (adjusted dosimetric challenge). The adjusted dosimetric and continuous output challenges were performed twice on separate days to assess for repeatability. All challenges were matched for dose at each dose step. The mean PD20ratio of the standard dosimetric challenge to the adjusted dosimetric challenge was 0.90 (95% CI 0.66–1.23, p=0.49) and intraclass correlation coefficient (ICC) was 0.82. Repeated adjusted dosimetric challenges had an ICC 0.62 for PD20. Repeated continuous output challenges had an ICC 0.74 for PD20. The adjusted dosimetric and continuous output challenges correlated (r=0.69, p=0.0043; ICC 0.65), but PD20was higher for the adjusted dosimetric challenge (mean PD20ratio 2.31, 95% CI 1.57–3.40; p=0.0004).Tidal dosimetric methacholine challenge using adjustment of nebuliser output produces results with good repeatability. The results of this adjusted dosimetric method differed from the continuous output method, underscoring that the results of different methacholine challenge methodologies may not be directly comparable.

1 November 2023 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JDJames Dean
James Dean
DSDave Singh
Dave Singh
Introduction: Specific resistance (SRaw) measurements in Chronic Obstructive Pulmonary Disease (COPD) patients may be performed by panting or tidal breathing. The aim of this study was to compare how breathing frequency affected SRaw in COPD and compare different tangent plotting methods. Methods: Fifteen COPD patients participated. Three protocols were performed: tidal 1 – spontaneous tidal breathing; tidal 2 – tidal breathing with a flow of ± 1 L/sec; panting – 60 breaths per min. Effective (SReff), total (SRtot), ± 0.5 L/s (SR0.5), and mid (SRmid) specific resistance were assessed. Results: The tidal breathing protocols provided similar results. Panting resulted in higher SReff (p = 0.0002) and SRtot (p < 0.0001) versus tidal breathing, but not SR0.5 or SRmid. Breathing frequency did not affect intra-test variance. SReff and SRtot measurements were similar, and were higher than SR0.5, during tidal breathing (p = 0.0014 and p < 0.0001 respectively) and panting (p = 0.0179 and p < 0.0001 respectively). SRtot was higher than SRmid during tidal breathing (p < 0.0001) and panting (p < 0.0001). Intra-test variance of SReff and SRtot were similar and showed the lowest percent coefficient of variation during both tidal breathing and panting. Conclusion: Panting and tidal breathing manoeuvres are not interchangeable in COPD patients. Panting widens the clubbing in the SRaw loop. SR0.5 and SRmid may underestimate abnormal physiology in COPD. Plain Language Summary: The effort to breathe can be measured as specific airway resistance (SRaw), which is a measure of the airflow that a person can achieve. SRaw is calculated from a plotted loop, but may be affected by the way that the test is performed and calculated. SRaw can be measured during panting or tidal breathing, and can be calculated using different methods of plotting the SRaw slope. In COPD patients, we found that panting SRaw is higher than during tidal breathing, and the calculation methods that use the extremities of the SRaw loop give higher values and have the lowest variability.